Eydenzelt receives FDA approval for four retinal diseases
diabetic macular edema

Eydenzelt receives FDA approval for four retinal diseases

Eydenzelt is approved for use in treating wet age-related macular degeneration, macular edema following reetinal vein occlusion, diabetic macular edema and diabetic retinopathy.
Retinal vein occlusion may be helped by new eye drops
blindness

Retinal vein occlusion may be helped by new eye drops

Retinal vein occlusion is a major cause of blindness that is caused by a blockage in the major vein that drains blood from the retina.